Home
Clinical Trials
mFOLFIRINOX Versus mFOLFOX Wi...

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

382 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-31

Study Completion Date

2028-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499

Acinar Cell Adenocarcinoma of the Pancreas Adenocarcinoma of the Gallbladder Adenocarcinoma of Unknown Primary +37 more

COMPLETED PHASE1

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

NCT05476796

Gastric Adenocarcinoma Esophagus Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

RECRUITING PHASE2

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

NCT07021950

Colorectal Cancer Ivonescimab

NOT_YET_RECRUITING PHASE2

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

NCT02344810

Adenocarcinoma of the Esophagus Adenocarcinoma of the Gastroesophageal Junction Diffuse Adenocarcinoma of the Stomach +11 more

WITHDRAWN PHASE1/PHASE2

A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis

NCT06048146

Lymph Node Metastasis Cancer of Rectum and Anus Oxaliplatin +4 more

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To determine if overall survival (OS) is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma.

SECONDARY OBJECTIVES:

I. To compare other indices of efficacy, including progression-free survival, objective response rates and duration of response between both treatment arms.

II. To evaluate safety and tolerability associated with treatment in each of the treatment arms.

III. To evaluate the proportion of patients receiving second line of therapy in both arms.

IV. To evaluate tolerability of the treatment in both arms using Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE).

EXPLORATORY OBJECTIVES:

I. Exploratory correlative markers will also be measured and evaluated within and between arms to better assess mechanisms and prognostic impact of markers on impact. These will include baseline PD-L1 combined positive score (CPS) and cell free deoxyribonucleic acid (cfDNA) before and after treatment.

II. To evaluate and assess the feasibility and compliance associated with not centrally collecting perceived attribution of protocol treatment to reported adverse events.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive fluorouracil intravenously (IV), leucovorin calcium IV, oxaliplatin IV, and irinotecan IV on study and nivolumab IV as clinically indicated. Patients undergo magnetic resonance imaging (MRI) and a computed tomography (CT) scan throughout the trial. Patients may also undergo blood sample collection on study.

ARM II: Patients receive fluorouracil IV, leucovorin calcium IV, and oxaliplatin IV on study and nivolumab IV as clinically indicated. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Esophageal Adenocarcinoma Advanced Gastric Adenocarcinoma Advanced Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Metastatic Esophageal Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Unresectable Esophageal Adenocarcinoma Unresectable Gastric Adenocarcinoma Unresectable Gastroesophageal Junction Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

2,4-Dioxo-5-fluoropyrimidine 5 Fluorouracil 5 Fluorouracilum 5 FU 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione, 1492-18-8 5-Formyl Tetrahydrofolate Calcium (6S)-Folinate Calcium Folinate 1-OHP Dacotin Dacplat ELOXATIN MDX-1106 Opdivo MRI CAT Scan Computed Axial Tomography CT Scan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologic documentation: HER2 negative adenocarcinoma as defined by American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (Bartley et al., Journal of Clinical Oncology \[JCO\] 2017) with known PD-L1 CPS (Any CPS is allowed, but should be known prior to registration)
* Stage: unresectable or metastatic
* Tumor site: esophagus, gastroesophageal junction, or stomach
* Measurable disease or non-measurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* No prior treatment for unresectable or metastatic disease
* Prior neoadjuvant or adjuvant cytotoxic chemotherapy or adjuvant immunotherapy is allowed as long as it was completed at least 1 year prior to registration
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Creatinine =\< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance \>= 30 mL/min
* Total bilirubin =\< 1.5 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (in patients with liver metastasis: =\< 5 x ULN if clearly attributable to liver metastases)
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:

* On effective anti-retroviral therapy
* Undetectable HIV viral load by standard clinical assay =\< 6 months of registration
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
* Patients who will receive nivolumab in addition to chemotherapy must not have any contraindications to immune checkpoint inhibitors

* Patients must not have active autoimmune disease that has required systemic treatment within 6 months prior to registration. Patients are permitted to receive immunotherapy if they have vitiligo, type I diabetes, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
* Patients must not have a condition requiring systemic treatment with either corticosteroids (\>10mg/day prednisone equivalents) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses (=\< 10mg/day prednisone equivalent) are permitted
* Patients must not have a history of noninfectious pneumonitis requiring steroids
* Patients with prior immune mediated adverse events related to immunotherapy that resulted in permanent treatment discontinuation with these agents are ineligible
* This study includes the use of the mandatory patient completed measure, PRO-CTCAE. For this study the PRO-CTCAE is available in English, Spanish, Korean, Chinese (Simplified), and Russian, hence patients must be able to speak, understand and read in these languages. Ad-hoc translation of patient-reported measures is not permitted

Exclusion Criteria

* Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects

\* Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =\< 7 days prior to registration is required
* No known Gilbert's syndrome or known homozygosity for UGAT1A1\*28 polymorphism
* No baseline grade \>= 2 peripheral neuropathy, neurosensory toxicity, or neuromotor toxicity per CTCAE version (v) 5.0 regardless of causality
* No medical condition such as uncontrolled infection or uncontrolled diabetes mellitus which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
* No untreated, symptomatic brain metastasis. Patients with treated brain metastases are eligible if the following criteria are met: 1) follow-up brain imaging done at least in 4 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression and 2) the patient no longer requires steroids, or is on a stable steroid dose for more than four weeks
* No allogeneic tissue/organ transplant

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Reach out to these primary contacts for questions about participation or study logistics.

Aishwarya Vijendran

Role: CONTACT

[email protected]

773-834-9613

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

800-378-9373

Site Public Contact

Role: primary

[email protected]

501-906-4199

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

702-384-0013

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Role: primary

213-388-0908

Site Public Contact

Role: primary

[email protected]

323-865-0451

Site Public Contact

Role: primary

323-865-0451

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

760-834-3798

Role: primary

[email protected]

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

877-642-4691

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Role: primary

[email protected]

Site Public Contact

Role: primary

970-203-7083

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

Role: primary

202-444-2223

Site Public Contact

Role: primary

202-741-2210

Site Public Contact

Role: primary

[email protected]

239-343-9660

Role: primary

954-265-4325

Site Public Contact

Role: primary

800-648-1935

Site Public Contact

Role: primary

Role: primary

618-463-5623

Site Public Contact

Role: primary

[email protected]

630-978-6212

Site Public Contact

Role: primary

[email protected]

Role: primary

312-864-5204

Site Public Contact

Role: primary

312-355-3046

Site Public Contact

Role: primary

[email protected]

773-702-8222

Role: primary

815-285-7800

Site Public Contact

Role: primary

[email protected]

630-275-1270

Site Public Contact

Role: primary

[email protected]

800-446-5532

Site Public Contact

Role: primary

[email protected]

217-876-4762

Role: primary

800-323-8622

Site Public Contact

Role: primary

[email protected]

773-702-8222

Site Public Contact

Role: primary

[email protected]

309-243-3605

Role: primary

815-664-4141

Site Public Contact

Role: primary

[email protected]

309-243-3605

Site Public Contact

Role: primary

[email protected]

779-696-9378

Site Public Contact

Role: primary

217-545-7929

Role: primary

219-310-2550

Site Public Contact

Role: primary

[email protected]

855-702-8222

Site Public Contact

Role: primary

219-924-8178

Role: primary

219-836-3349

Site Public Contact

Role: primary

Role: primary

Site Public Contact

Role: primary

[email protected]

913-948-5588

Role: primary

[email protected]

Site Public Contact

Role: primary

888-446-3729

Site Public Contact

Role: primary

[email protected]

785-452-7038

Site Public Contact

Role: primary

785-295-8000

Role: primary

[email protected]

734-712-7251

Site Public Contact

Role: primary

248-551-7695

Site Public Contact

Role: primary

[email protected]

734-712-7251

Site Public Contact

Role: primary

248-551-7695

Site Public Contact

Role: primary

248-551-7695

Role: primary

218-365-7900

Site Public Contact

Role: primary

[email protected]

218-786-3308

Site Public Contact

Role: primary

218-786-3308

Role: primary

218-485-4481

Site Public Contact

Role: primary

[email protected]

952-993-1517

Site Public Contact

Role: primary

[email protected]

218-786-3308

Site Public Contact

Role: primary

218-568-4416

Role: primary

218-894-7870

Site Public Contact

Role: primary

[email protected]

952-993-1517

Role: primary

605-312-3320

Site Public Contact

Role: primary

[email protected]

952-993-1517

Site Public Contact

Role: primary

888-446-3729

Site Public Contact

Role: primary

[email protected]

913-948-5588

Site Public Contact

Role: primary

417-269-4520

Site Public Contact

Role: primary

888-446-3729

Site Public Contact

Role: primary

[email protected]

573-334-2230

Role: primary

816-404-4375

Site Public Contact

Role: primary

[email protected]

573-302-2768

Role: primary

314-996-5569

Site Public Contact

Role: primary

417-269-4520

Site Public Contact

Role: primary

417-269-4520

Site Public Contact

Role: primary

888-446-3729

Site Public Contact

Role: primary

Role: primary

800-648-6274

Site Public Contact

Role: primary

[email protected]

406-969-6060

Role: primary

402-334-4773

Site Public Contact

Role: primary

402-354-5144

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

702-384-0013

Site Public Contact

Role: primary

[email protected]

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

702-384-0013

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Role: primary

[email protected]

Role: primary

518-926-6700

Site Public Contact

Role: primary

516-734-8896

Role: primary

701-234-6161

Site Public Contact

Role: primary

605-312-3320

Role: primary

937-276-8320

Site Public Contact

Role: primary

[email protected]

937-528-2900

Site Public Contact

Role: primary

[email protected]

937-528-2900

Site Public Contact

Role: primary

[email protected]

614-488-2745

Role: primary

[email protected]

503-215-2614

Role: primary

215-456-3880

Site Public Contact

Role: primary

[email protected]

800-275-6401

Site Public Contact

Role: primary

[email protected]

570-703-4768

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

800-782-8581

Site Public Contact

Role: primary

[email protected]

952-993-1517

Role: primary

701-364-6272

Site Public Contact

Role: primary

[email protected]

414-302-2304

Site Public Contact

Role: primary

262-928-7632

Site Public Contact

Role: primary

[email protected]

262-928-5539

Role: primary

715-422-7718

Site Public Contact

Role: primary

[email protected]

800-782-8581

Site Public Contact

Role: primary

[email protected]

773-702-9171

Site Public Contact

Role: primary

[email protected]

800-996-2663

Site Public Contact

Role: primary

787-395-7085

Site Public Contact

Role: primary

787-780-2865

Site Public Contact

Role: primary

787-621-4397

Role: primary

787-763-1296

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2022-08569

Identifier Type: OTHER

Identifier Source: secondary_id

A022102

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

NCT03783936 COMPLETED PHASE2

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

NCT02366819 RECRUITING PHASE4

Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus

NCT00005607 UNKNOWN PHASE2

Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin

NCT00976768 COMPLETED PHASE2

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

NCT04442984 UNKNOWN PHASE2

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968 RECRUITING PHASE2

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709 RECRUITING PHASE2

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

NCT04757363 ACTIVE_NOT_RECRUITING PHASE2

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

NCT05945901 ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00006115 UNKNOWN PHASE2

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

NCT05610163 ACTIVE_NOT_RECRUITING PHASE2

A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors

NCT00001579 COMPLETED PHASE1

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02333188 COMPLETED PHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768 RECRUITING PHASE1

Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients

NCT06812728 RECRUITING PHASE2

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551 COMPLETED PHASE2

Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

NCT00004931 COMPLETED PHASE3

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT00957905 COMPLETED PHASE2

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

NCT00654160 COMPLETED PHASE1

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

NCT07042685 RECRUITING PHASE2

A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

NCT03641976 UNKNOWN PHASE2

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

NCT05564403 ACTIVE_NOT_RECRUITING PHASE2

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

NCT03837977 COMPLETED PHASE2

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

NCT01246960 COMPLETED PHASE2

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

NCT00068692 COMPLETED PHASE3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Study Results

Basic Information

Brief Summary

Related Clinical Trials

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis

Detailed Description

Conditions

Study Design

Study Groups

Arm I (mFOLFIRINOX, nivolumab)

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Irinotecan

Nivolumab

Magnetic Resonance Imaging

Computed Tomography

Biospecimen Collection

Questionnaire Administration

Arm II (mFOLFOX, nivolumab)

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Nivolumab

Magnetic Resonance Imaging

Computed Tomography

Biospecimen Collection

Questionnaire Administration

Interventions

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Irinotecan

Nivolumab

Magnetic Resonance Imaging

Computed Tomography

Biospecimen Collection

Questionnaire Administration

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

National Cancer Institute (NCI)

Alliance for Clinical Trials in Oncology

Responsible Party

Locations

Springfield Clinic

Springfield Memorial Hospital

Carle Cancer Center

Illinois CancerCare - Washington

Rush-Copley Healthcare Center

University of Alabama at Birmingham Cancer Center

Anchorage Associates in Radiation Medicine

Anchorage Radiation Therapy Center

Alaska Breast Care and Surgery LLC

Alaska Oncology and Hematology LLC

Alaska Women's Cancer Care

Anchorage Oncology Centre

Katmai Oncology Group

Providence Alaska Medical Center

Fairbanks Memorial Hospital

Kingman Regional Medical Center

Cancer Center at Saint Joseph's

Mercy Hospital Fort Smith

CARTI Cancer Center

Kaiser Permanente-Deer Valley Medical Center

Mission Hope Medical Oncology - Arroyo Grande

PCR Oncology

Sutter Auburn Faith Hospital

Sutter Cancer Centers Radiation Oncology Services-Auburn

Alta Bates Summit Medical Center-Herrick Campus

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Mills-Peninsula Medical Center

Sutter Cancer Centers Radiation Oncology Services-Cameron Park